Loss Sharing Agreement, Amount

No definition available.

Name:	mnkd_LossSharingAgreementAmount
Namespace Prefix:	mnkd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Milestone Payments

+ References

No definition available.

+ Details

Name:	mnkd_PotentialMilestonePayments
Namespace Prefix:	mnkd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Milestone Payments To Be Received

+ References

No definition available.

+ Details

Name:	mnkd_PotentialMilestonePaymentsToBeReceived
Namespace Prefix:	mnkd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Profit Loss Sharing Agreement Allocation Percentage

+ References

No definition available.

+ Details

Name:	mnkd_ProfitLossSharingAgreementAllocationPercentage
Namespace Prefix:	mnkd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Termination Date Of License Agreement

+ References

No definition available.

+ Details

Name:	mnkd_TerminationDateOfLicenseAgreement
Namespace Prefix:	mnkd_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Fee

+ References

No definition available.

+ Details

Name:	mnkd_UpfrontFee
Namespace Prefix:	mnkd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 16
-Article 9

+ Details

Name:	us-gaap_DebtInstrumentCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 17
-Article 5

+ Details

Name:	us-gaap_DeferredCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

+ Details

Name:	us-gaap_LongTermLoansPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name:	us-gaap_PaidInKindInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name:	us-gaap_ProceedsFromRelatedPartyDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=mnkd_SanofiAventisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=stpr_CA
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mnkd_MilestoneEventsAxis=mnkd_ManufacturingMilestoneEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mnkd_MilestoneEventsAxis=mnkd_DevelopmentMilestoneEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mnkd_MilestoneEventsAxis=mnkd_FilingAndCompletionOfRegulatoryApprovalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mnkd_MilestoneEventsAxis=mnkd_AchievementOfProductSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=mnkd_OperatingLossSharingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangement - Additional Information (Detail) - USD ($)				3 Months Ended	12 Months Ended
	Feb. 10, 2016	Jan. 04, 2016	Aug. 11, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Paid-in-kind interest					$ 1,652,000
Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Carrying value					44,500,000	$ 3,000,000
Sanofi-Aventis Deutschland GmbH \| CALIFORNIA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Carrying value					$ 17,900,000
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Up-front fee				$ 150,000,000
Potential milestone payment			$ 775,000,000
Profits and losses sharing percentage			35.00%		35.00%
Maximum secured loan facility							$ 175,000,000
Senior notes, effective interest rate							8.50%
License and Collaboration Agreement with Sanofi \| Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Termination date		Jul. 04, 2016
License and Collaboration Agreement with Sanofi \| Manufacturing Milestone Events
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments earned						$ 50,000,000
License and Collaboration Agreement with Sanofi \| Development Milestone Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment			$ 75,000,000
License and Collaboration Agreement with Sanofi \| Regulatory Approvals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment			50,000,000
License and Collaboration Agreement with Sanofi \| Product Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment			$ 650,000,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Up-front fee					$ 150,000,000
Profits and losses sharing percentage			65.00%		65.00%
Deferred revenue from collaboration product shipments					$ 150,000,000
Milestone receivable					50,000,000
Deferred cost					13,500,000
Company's total portion of loss sharing					57,700,000
Maximum secured loan facility					175,000,000
Carrying value					44,500,000
Secured loan facility, amount borrowed					44,500,000
Secured loan facility, amount owed					62,400,000
Paid-in-kind interest					1,700,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Secured loan facility, amount borrowed	$ 17,900,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| Operating loss Sharing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Company's total portion of loss sharing					60,700,000
License and Collaboration Agreement with Sanofi \| Sanofi-Aventis Deutschland GmbH \| AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue from collaboration product shipments					$ 17,500,000